H. Ribaudo

发表

Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.

C. Fichtenbaum, K. Robertson, B. Taiwo, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Jack T Stapleton, Stuart Haber, David Heckerman, 2010, Science.

Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.

P. Douglas, E. Gardner, Kathleen V Fitch, 2020, The Journal of infectious diseases.

Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics

D. Lauffenburger, F. Pereyra, D. Kuritzkes, 2014, Open forum infectious diseases.

Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery

J. Mellors, J. Currier, T. Wilkin, 2015, AIDS.

Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection

J. Currier, J. Stein, T. Brown, 2013, AIDS.

Birth weight for gestational age norms for a large cohort of infants born to HIV-negative women in Botswana compared with norms for U.S.-born black infants

S. Lockman, H. Ribaudo, M. Essex, 2011, BMC pediatrics.

Antiretroviral Regimen and Suboptimal Medication Adherence Are Associated With Low-Level Human Immunodeficiency Virus Viremia

D. Bangsberg, Jonathan Z. Li, K. Ragland, 2015, Open forum infectious diseases.

Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.

C. Moser, J. Currier, T. Kelesidis, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia

D. Kuritzkes, D. Bangsberg, Jonathan Z. Li, 2014, AIDS.

Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy: Results of ACTG A5095

D. Kuritzkes, B. Schackman, A. Krambrink, 2007, Journal of acquired immune deficiency syndromes.

Cost-effectiveness evaluation to inform clinical trial design.

H. Ribaudo, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure

K. Metzner, M. Kozal, R. Paredes, 2011 .

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.

G. Bloomfield, M. Kozal, K. Tashima, 2020, The Journal of infectious diseases.

Effects of HIV Infection on Arterial Endothelial Function

J. Currier, J. Stein, C. Korcarz, 2020, Arteriosclerosis, thrombosis, and vascular biology.

Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.

M. Lederman, P. Ridker, C. Fichtenbaum, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate: AIDS Clinical Trials Group Study A5314

P. Ridker, J. Currier, J. Stein, 2018, Arteriosclerosis, thrombosis, and vascular biology.

Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.

K. Tashima, D. Kuritzkes, C. Shikuma, 2011, AIDS Research and Human Retroviruses.

Three Nonnucleoside Reverse Transcriptase InhibitorSparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

H. Ribaudo, R. Landovitz, J. Lennox, 2015, Annals of Internal Medicine.

Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial

G. Bloomfield, C. Fichtenbaum, K. Ruxrungtham, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Quality of Life Following Surgery for Intracranial Meningiomas at Brigham and Women's Hosipital: A Study of 164 Patients Using a Modification of the Functional Assessment of Cancer Therapy–brain Questionnaire

P. Black, S. Kalkanis, A. Quiñones‐Hinojosa, 2000, Journal of Neuro-Oncology.

A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness

J. Currier, J. Stein, T. Brown, 2015, AIDS.

Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2019, American heart journal.

HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States

D. Kuritzkes, J. Currier, S. Cohn, 2016, AIDS and Behavior.

Periconception HIV Risk Behavior Among Men and Women Reporting HIV-Serodiscordant Partners in KwaZulu-Natal, South Africa

D. Bangsberg, C. Milford, S. Safren, 2015, AIDS and Behavior.

Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation

T. Brown, G. McComsey, M. Yin, 2015, Annals of Internal Medicine.

Reply to Tong et al.

D. Haas, E. Acosta, H. Ribaudo, 2006 .

Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2019, American heart journal.

A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen

S. Hammer, J. Mellors, K. Squires, 2010 .

Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.

D. Kuritzkes, B. Schackman, E. Acosta, 2008, Journal of Infectious Diseases.

Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation

T. Brown, G. McComsey, M. Yin, 2017, AIDS.

Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

O. Yang, C. Moser, J. Currier, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV

G. Bloomfield, C. Fichtenbaum, P. Douglas, 2022, Journal of acquired immune deficiency syndromes.

Incorporating estimands into clinical trial statistical analysis plans

J. Lindsey, Minhee Kang, L. Smeaton, 2022, Clinical trials.

Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators.

P. Douglas, U. Hoffmann, S. Grinspoon, 2020, The Journal of infectious diseases.

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.

D. Clifford, M. Ritchie, G. Robbins, 2010, The Journal of infectious diseases.

Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.

O. Yang, C. Moser, J. Currier, 2015, The Journal of infectious diseases.

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1A Randomized, Controlled Equivalence TrialNNRTI-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

D. Kuritzkes, C. Fichtenbaum, D. Haas, 2014 .

COVID-19 Vaccination Rates in a Global HIV Cohort.

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2021, The Journal of infectious diseases.

Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

O. Yang, C. Moser, J. Currier, 2016, The Journal of infectious diseases.

PROSPECTIVE RANDOMIZED CLINICAL TRIAL OF THE EFFECTS OF THREE MODERN ANTIRETROVIRAL THERAPIES ON CAROTID INTIMA-MEDIA THICKNESS IN HIV-INFECTED INDIVIDUALS (AIDS CLINICAL TRIALS GROUP STUDY A5260S)

T. Brown, J. Currier, J. Stein, 2014 .

Changes in Plasma Levels of Oxidized Lipoproteins and Lipoprotein Subfractions with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy and Associations with Common Carotid Artery Intima-Media Thickness: ACTG 5260s

O. Yang, C. Moser, J. Currier, 2016, Antiviral therapy.

Methotrexate Inhibits T Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living With HIV

M. Lederman, D. Moisi, J. Currier, 2022, Frontiers in Immunology.

Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

Michael T. Lu, G. Bloomfield, C. Fichtenbaum, 2021, Journal of acquired immune deficiency syndromes.

Vitamin D does not Modulate Immune-Mediated Bone loss during ART Initiation

T. Brown, M. Yin, K. Melbourne, 2019, Antiviral therapy.

A Randomized, Double-Blinded, Placebo-Controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed HIV Infection.

K. Yarasheski, J. Lake, Brett Williams, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir

C. Fichtenbaum, B. Taiwo, T. Brown, 2016, AIDS.

Prevention of HIV-1 infection with early antiretroviral therapy.

Lei Wang, David Burns, Kenneth H Mayer, 2011, The New England journal of medicine.

Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.

P. Sax, D. Haas, E. Daar, 2013, The Journal of infectious diseases.

Amdoxovir versus Placebo with Enfuvirtide plus Optimized Background Therapy for HIV-1-Infected Subjects Failing Current Therapy (Aactg A5118)

S. Hammer, D. Kuritzkes, J. Gerber, 2005, Antiviral therapy.

A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.

S. Hammer, J. Mellors, K. Squires, 2010, HIV clinical trials.

Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial.

G. Bloomfield, K. Tashima, G. Robbins, 2020, The Journal of infectious diseases.

Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease risk

G. Bloomfield, C. Fichtenbaum, K. Ruxrungtham, 2022, AIDS.

Eff ects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection : results from the phase 3 HPTN 052 randomised controlled trial

D. Havlir, J. Gallant, S. Swindells, 2014 .

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Christopher D Pilcher, Edward P Acosta, Daniel R Kuritzkes, 2004, The New England journal of medicine.

Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.

D. Kuritzkes, A. Krambrink, C. Shikuma, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study

Catia Marzolini, Edward P Acosta, D. Clifford, 2004, AIDS.

Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.

Iain J. MacLeod, S. Lockman, H. Ribaudo, 2010, AIDS research and human retroviruses.

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

Roger Paredes, Victoria A Johnson, Daniel R Kuritzkes, 2010, The Journal of infectious diseases.

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.

Edward P Acosta, Victoria A Johnson, Daniel R Kuritzkes, 2008, The Journal of infectious diseases.

Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.

D. Haas, U. Lalloo, E. Acosta, 2013, The Journal of infectious diseases.

Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s)

D. Clifford, S. Evans, E. Acosta, 2009, HIV clinical trials.

HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.

S. Hammer, M. Fischl, L. Demeter, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Christopher D Pilcher, Edward P Acosta, Daniel R Kuritzkes, 2006, JAMA.

Design Issues in Initial HIV-Treatment Trials: Focus on Actg A5095

D. Kuritzkes, B. Schackman, E. Acosta, 2005, Antiviral therapy.

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

David W. Haas, Todd T. Brown, Daniel R. Kuritzkes, 2014, Annals of internal medicine.

Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana.

S. Lockman, H. Ribaudo, S. Dryden-Peterson, 2012, The Journal of infectious diseases.

Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases

R. Haubrich, J. Fellay, A. Telenti, 2011, HIV clinical trials.

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

Marylyn D Ritchie, Gene D Morse, Benjamin J. Grady, 2012, Pharmacogenetics and genomics.

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols

R. Haubrich, P. D. de Bakker, G. Robbins, 2015, Pharmacogenetics and genomics.

Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.

R. Haubrich, D. Kuritzkes, B. Taiwo, 2011, The Journal of infectious diseases.

Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.

H. Ribaudo, R. Shapiro, K. Powis, 2012, AIDS.

Cardiac risk: not so simple.

J. Aberg, H. Ribaudo, 2010, The Journal of infectious diseases.

A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

S. Hammer, M. Saag, A. Collier, 2003, The Journal of infectious diseases.

Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial

D. Kuritzkes, R. Bosch, H. Ribaudo, 2000, AIDS.

HIV-exposed children account for more than half of 24-month mortality in Botswana

S. Lockman, H. Ribaudo, M. Essex, 2016, BMC Pediatrics.

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.

K. Tashima, D. Kuritzkes, D. Clifford, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.

K. Metzner, M. Kozal, R. Paredes, 2013, The Journal of infectious diseases.

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure

M. Kozal, R. Paredes, D. Kuritzkes, 2012, AIDS.

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings

D. Katzenstein, J. Crump, J. Bartlett, 2012, AIDS.

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.

Kenneth H Mayer, Ian Sanne, Max Essex, 2014, The Lancet. Infectious diseases.

Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study

Ross J. Harris, R. Haubrich, J. Sterne, 2011, Journal of acquired immune deficiency syndromes.

Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death.

D. Kitch, J. Stein, P. Tebas, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.

R. Haubrich, G. Robbins, C. Flexner, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Risk factors for very preterm delivery and delivery of very‐small‐for‐gestational‐age infants among HIV‐exposed and HIV‐unexposed infants in Botswana

H. Ribaudo, M. Essex, R. Shapiro, 2011, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus.

P. Douglas, P. Muntner, G. McComsey, 2020, The Journal of infectious diseases.

Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)

K. Tashima, D. Kuritzkes, C. Shikuma, 2007, Journal of acquired immune deficiency syndromes.

Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE.

J. Schrack, P. Douglas, S. Henn, 2020, The Journal of infectious diseases.

Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia

L. Olson, D. Haas, J. Currier, 2015, Open forum infectious diseases.

Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV.

J. Currier, J. Stein, F. Aweeka, 2020, Journal of acquired immune deficiency syndromes.

9 Ribaudo

D. Kuritzkes, B. Schackman, E. Acosta, 2006 .

Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

D. Kuritzkes, R. Leavitt, L. Na, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trial

C. Fichtenbaum, J. Aberg, S. Grinspoon, 2022, Contemporary clinical trials.

Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus

C. Fichtenbaum, P. Douglas, J. Currier, 2021, Open forum infectious diseases.

Drug susceptibility and resistance mutations after first-line failure in resource limited settings.

D. Katzenstein, J. Bartlett, W. Stevens, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy.

Heather Ribaudo, Judith Feinberg, M. Chesney, 2005, The Journal of infectious diseases.

Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV

C. Fichtenbaum, J. Currier, J. Aberg, 2023, eBioMedicine.

Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States

Michael T. Lu, G. Bloomfield, C. Fichtenbaum, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A joint analysis of quality of life and survival using a random effect selection model.

S. Thompson, H. Ribaudo, T. Allen-Mersh, 2000, Statistics in medicine.

Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV

Michael T. Lu, G. Bloomfield, C. Fichtenbaum, 2022, AIDS.

Body Composition, Soluble Markers of Inflammation, and Bone Mineral Density in Antiretroviral Therapy–Naive HIV-1–Infected Individuals

J. Currier, J. Stein, T. Brown, 2013, Journal of acquired immune deficiency syndromes.

No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.

J. Lok, R. Bosch, A. Collier, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation

T. Brown, G. McComsey, M. Yin, 2017, Open forum infectious diseases.

Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity

V. Johnson, J. Mellors, J. Bremer, 2015, Journal of Clinical Microbiology.

Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression

D. Kuritzkes, K. Squires, B. Schackman, 2007, AIDS.

Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.

D. Katzenstein, J. Crump, J. Bartlett, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A multilevel analysis of longitudinal ordinal data: evaluation of the level of physical performance of women receiving adjuvant therapy for breast cancer

Simon G. Thompson, H. Ribaudo, H. J. Ribaudo, 1999 .

Use of Biological Knowledge to Inform The Analysis of Gene-Gene Interactions Involved in Modulating Virologic Failure with Efavirenz-Containing Treatment Regimens in Art-Naive Actg Clinical Trials Participants

Marylyn D. Ritchie, David W. Haas, Eric Torstenson, 2011, Pacific Symposium on Biocomputing.

Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy.

D. Kuritzkes, T. Henrich, H. Ribaudo, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hyperlipidaemia in HIV-Infected Patients on Lopinavir/Ritonavir Monotherapy in Resource-Limited Settings

M. Hughes, J. Bartlett, M. Hosseinipour, 2016, Antiviral therapy.

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection

R. Haubrich, D. Havlir, J. Mellors, 2011, AIDS.

Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial

D. Haas, P. Bacchetti, J. Currier, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy

J. Currier, H. Ribaudo, R. Gulick, 2019, Open forum infectious diseases.

Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination

A. Rancourt, C. Fichtenbaum, P. Douglas, 2020, HIV research & clinical practice.

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial

H. Ribaudo, Xianmixikemaier Abulizi, P. Flandre, 2019, Journal of Acquired Immune Deficiency Syndromes.

Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2021, JAMA network open.

Cost-Effectiveness Analysis of Ugt1A1 Genetic Testing to Inform Antiretroviral Prescribing in HIV Disease

K. Freedberg, P. Sax, D. Haas, 2013, Antiviral therapy.

Title Screening for UGT 1 A 1 Genotype in Study A 5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia Permalink

L. Olson, D. Haas, J. Currier, 2015 .

The analysis of repeated multivariate binary quality of life data: a hierarchical model approach

S G Thompson, H J Ribaudo, S. Thompson, 2002, Statistical methods in medical research.

Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.

D. Kuritzkes, K. Squires, C. Shikuma, 2007, The Journal of infectious diseases.

Associations of Muscle Density and Area With Coronary Artery Plaque and Physical Function

C. Fichtenbaum, P. Sax, D. Haas, 2023, Journal of acquired immune deficiency syndromes.

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

R. Paredes, V. Johnson, D. Kuritzkes, 2010, The Journal of infectious diseases.

Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.

K. Metzner, M. Kozal, R. Paredes, 2013, Journal of Infectious Diseases.

A comparison of three initial antiretroviral AIDS regimens.

D. Kuritzkes, H. Ribaudo, R. Gulick, 2007, The New England journal of medicine.

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols

R. Haubrich, P. D. de Bakker, G. Robbins, 2015, Pharmacogenetics and genomics.

Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.

Michael T. Lu, G. Bloomfield, C. Fichtenbaum, 2023, The New England journal of medicine.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

R. C. Rose, Todd M. Allen, David S. Rubin, 2010, Science.

Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.

O. Yang, C. Moser, J. Currier, 2015, The Journal of infectious diseases.

Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: a Longitudinal Analysis of REPRIEVE data.

C. Fichtenbaum, J. Aberg, S. Grinspoon, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s)

D. Clifford, S. Evans, E. Acosta, 2009, HIV clinical trials.

Cytomegalovirus IgG is Associated With Physical Function But Not Muscle Density in People With HIV

C. Fichtenbaum, T. Burdo, H. Ribaudo, 2024, Journal of acquired immune deficiency syndromes.

Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir

C. Fichtenbaum, T. Brown, A. Landay, 2016, AIDS.